Oral Micronized Progesterone Cost in California (2026)

How Much Does Oral Micronized Progesterone Cost in California in 2026?
At a glance
- Average California cash price (generic) / $45 per month
- Brand Prometrium list price / $180 per month
- Compounded progesterone (503A pharmacy) / approximately $25 per month
- Medi-Cal coverage status / covered with prior authorization
- Dosage form / oral capsule, 100 mg or 200 mg
- Standard dosing / 200 mg nightly (continuous) or 200 mg days 1 through 12 of cycle (cyclic)
- Telehealth prescribing in California / permitted
- Compounding legality / yes, via state-board-regulated 503A pharmacies
- Savings programs / manufacturer copay cards and GoodRx-type discount programs available
- FDA-approved indication / prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens
California Cash Prices for Oral Micronized Progesterone in 2026
The average cash price for a 30-day supply of generic oral micronized progesterone at California retail pharmacies is $45 in 2026. Brand-name Prometrium carries a manufacturer list price of $180 per month, though few patients pay that full amount. The FDA-approved labeling for Prometrium specifies 200 mg taken orally at bedtime for 12 sequential days per 28-day cycle when used alongside conjugated estrogens for endometrial protection 1.
Pricing varies by pharmacy chain and location within the state. Costco and independent pharmacies in the Central Valley and Inland Empire tend to price generics 10 to 20% below San Francisco or Los Angeles metro averages. Discount platforms like GoodRx and RxSaver can reduce cash prices further, sometimes below $20 for a 30-day supply of 100 mg capsules. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial established that oral micronized progesterone provides endometrial protection comparable to medroxyprogesterone acetate while producing a more favorable lipid profile 2. That finding drove widespread adoption of micronized progesterone, and the generic market that followed is what keeps California prices relatively accessible today.
Patients filling 200 mg capsules rather than doubling up on 100 mg capsules save between $5 and $15 per month. Ask your pharmacist about capsule-strength pricing before filling.
Medi-Cal Coverage for Oral Micronized Progesterone
Medi-Cal, California's Medicaid program, covers oral micronized progesterone with prior authorization. The prior authorization requirement exists because Medi-Cal formulary committees classify progesterone as a non-preferred agent in some managed care plans, requiring documentation that it is medically necessary for endometrial protection during estrogen therapy 3.
Prescribers must submit clinical justification. The most common approved indication is prevention of endometrial hyperplasia in women with an intact uterus receiving systemic estrogen, consistent with the 2022 Endocrine Society clinical practice guideline on hormone therapy in menopause 4. Once approved, Medi-Cal copays for generic progesterone are typically $0 to $3.
The North American Menopause Society (NAMS) 2022 position statement recommends adding a progestogen to estrogen therapy in all women with an intact uterus to reduce the risk of endometrial cancer 5. This recommendation strengthens prior authorization requests. Denial rates for progesterone PA in California Medi-Cal managed care plans are low when documentation includes the patient's menopausal status, uterine status, and concurrent estrogen prescription.
Processing typically takes 24 to 72 hours. If denied, patients can appeal through the Medi-Cal managed care plan's grievance process or request a state fair hearing.
Compounded Progesterone in California: Legality and Cost
Compounded progesterone is legal in California through 503A pharmacies operating under California State Board of Pharmacy oversight. These pharmacies compound patient-specific prescriptions using USP-grade micronized progesterone powder. A 30-day supply of compounded oral progesterone capsules averages $25 in California, making it the cheapest option available 6.
There is an important distinction. FDA-approved Prometrium and its generics undergo bioequivalence testing and carry standardized dissolution profiles. Compounded capsules do not. The American College of Obstetricians and Gynecologists (ACOG) recommends FDA-approved formulations over compounded versions when an FDA-approved product is available and accessible 7. A 2020 FDA advisory committee review found that compounded hormone preparations can vary in potency by 10 to 25% between batches 8.
California's 503A pharmacies must comply with California Business and Professions Code sections 4126 and 4127, which mandate quality assurance testing, proper labeling, and adverse event reporting. Patients choosing compounded progesterone should verify their pharmacy holds a current California Board of Pharmacy license and performs third-party potency testing.
Compounded progesterone may be appropriate when a patient has a documented allergy to peanut oil (the vehicle in brand Prometrium) or requires a non-standard dose. Generic formulations now use different oil bases, so peanut allergy alone may not necessitate compounding in 2026.
Insurance Coverage Beyond Medi-Cal
Most major commercial insurance plans in California include generic oral micronized progesterone on their formularies. Covered California marketplace plans (Bronze through Platinum tiers) list generic progesterone as a Tier 1 or Tier 2 drug, with copays ranging from $0 to $25 per month depending on the plan 9.
Kaiser Permanente Northern and Southern California formularies include generic micronized progesterone without prior authorization for endometrial protection. Blue Shield of California and Anthem Blue Cross typically require that progesterone be prescribed alongside a concurrent estrogen prescription for the claim to process without PA.
The Women's Health Initiative (WHI) trial data, which showed increased breast cancer risk with combined conjugated equine estrogen plus medroxyprogesterone acetate, prompted many clinicians to switch patients to micronized progesterone 10. The French E3N cohort study (N=80,377) found that micronized progesterone combined with transdermal estradiol did not significantly increase breast cancer risk over a mean follow-up of 8.1 years, while synthetic progestins did 11. These data points have made insurers more willing to cover micronized progesterone as the preferred progestogen.
For patients with high-deductible plans, generic micronized progesterone at $45 cash may cost less than running the prescription through insurance. Compare your plan's negotiated price against GoodRx or direct cash pricing before deciding.
Telehealth Access in California
California permits prescribing oral micronized progesterone via telehealth. The state's post-pandemic telehealth parity laws (SB 510, effective January 2022) require insurers to cover telehealth visits at the same rate as in-person visits, removing a prior financial barrier 12.
Telehealth consultations are particularly relevant for patients in rural California counties (Modoc, Lassen, Inyo, Alpine) where endocrinologists and menopause-certified providers are scarce. A 2021 study published in Menopause found that telehealth delivery of hormone therapy consultations produced equivalent patient satisfaction and adherence rates compared to in-person visits 13.
HealthRX and other telehealth platforms licensed in California can evaluate patients, order necessary labs (FSH, estradiol, lipid panel), and prescribe micronized progesterone shipped directly to the patient's home or sent to a local pharmacy. The standard clinical workflow involves confirming menopausal status, verifying that the patient has an intact uterus, reviewing contraindications including active liver disease or known hypersensitivity, and selecting the appropriate dosing schedule.
Continuous dosing (100 mg or 200 mg nightly) is typically prescribed for women more than 12 months past their final menstrual period. Cyclic dosing (200 mg for 12 to 14 days per month) suits women in the early postmenopausal window who prefer a monthly withdrawal bleed. Both approaches provide adequate endometrial protection per the 2017 NAMS position statement 14.
Discount Programs and Savings Strategies
Several pathways exist to reduce out-of-pocket costs for oral micronized progesterone in California. The brand manufacturer offers a Prometrium savings card that can reduce copays to as low as $25 per month for commercially insured patients. This card does not apply to government-funded insurance (Medi-Cal, Medicare Part D, Tricare).
Generic discount strategies are often more effective. GoodRx, RxSaver, and SingleCare coupons frequently bring the cash price of generic micronized progesterone to $15 to $30 for a 30-day supply at California Costco, Walmart, and CVS locations. No insurance is needed to use these coupons.
The Mark Cuban Cost Plus Drug Company offers generic micronized progesterone at manufacturer cost plus a 15% margin plus a $5 dispensing fee, shipped to California addresses. For some patients, this price undercuts local pharmacy pricing.
Medicare Part D enrollees should compare their plan's formulary tier and copay against these cash options. After the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, most Medicare patients filling only progesterone will not reach that threshold, but those on multiple branded medications may benefit from applying the cap strategically 15.
Patients with no insurance and income below 200% of the federal poverty level may qualify for patient assistance programs. NeedyMeds and RxAssist maintain updated databases of eligibility criteria and application forms.
Clinical Considerations Affecting Cost
Dose determines cost. The 100 mg capsule and the 200 mg capsule are priced similarly at most pharmacies, so patients prescribed 200 mg daily pay roughly the same as those on 100 mg. Patients prescribed 300 mg daily (sometimes used off-label for sleep or mood symptoms) will pay 1.5 to 2 times the standard monthly price, and insurance may not cover the higher dose without additional PA documentation.
Route of administration also matters. Vaginal administration of oral micronized progesterone capsules (an off-label but evidence-supported practice) may allow lower doses. A randomized trial by Levine and Watson found that 100 mg vaginally provided endometrial protection equivalent to 200 mg orally 16. This approach can halve the monthly capsule count and cost, though patients should discuss it with their prescriber since it is off-label.
The REPLENISH trial demonstrated that a combined estradiol/progesterone capsule (TX-001HR, marketed as Bijuva) provides both estrogen and progestogen in a single pill 17. Bijuva runs $150 to $200 per month in California without insurance, making separate generic estradiol plus generic progesterone ($20 to $60 total) the more affordable combination for most patients.
Progesterone should be taken at bedtime because it causes drowsiness. This sedating property, mediated by its metabolite allopregnanolone acting on GABA-A receptors, is well-documented and can benefit patients with concurrent insomnia 18. Taking the capsule with food increases bioavailability. The Prometrium label specifies administration with food to achieve adequate serum levels 1.
How to Get the Best Price in California
Start by checking whether your insurance covers generic micronized progesterone without PA. If it does, your copay is likely $0 to $25. If PA is required, ask your prescriber to submit it with documentation of concurrent estrogen use and intact uterus.
If you are paying cash, compare prices across at least three pharmacies using GoodRx or a similar tool. Costco pharmacies do not require a membership for pharmacy purchases in California (per state law). Independent pharmacies in less expensive zip codes often match or beat chain pricing.
If you have confirmed no allergy to peanut oil or other Prometrium excipients and your dose is standard (100 mg or 200 mg), generic FDA-approved capsules are the recommended option over compounding. Reserve compounded progesterone for cases with genuine clinical need, such as documented allergy or non-standard dosing.
For patients starting hormone therapy through telehealth, confirm that the platform's prescribers are California-licensed and that the pharmacy they use ships to your location or that you can transfer the prescription to a local pharmacy of your choice.
Frequently asked questions
›How much does oral micronized progesterone cost in California?
›Does California Medicaid cover oral micronized progesterone?
›Is compounded progesterone legal in California?
›Can I get oral micronized progesterone via telehealth in California?
›Which insurance plans cover oral micronized progesterone in California?
›What's the cheapest way to get oral micronized progesterone in California?
›Are there California oral micronized progesterone discount programs?
›How does the Prometrium savings card work in California?
›Is generic progesterone as effective as brand Prometrium?
›Does oral micronized progesterone require prior authorization in California?
References
- Prometrium (progesterone) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_cgi/index.cfm
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Stanczyk FZ, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171-208. https://pubmed.ncbi.nlm.nih.gov/12507660/
- Stuenkel CA, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26544531/
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35594071/
- Thompson JJ, et al. Examining the evidence for compounded bioidentical hormone therapy. Int J Pharm Compd. 2020;24(1):4-13. https://pubmed.ncbi.nlm.nih.gov/31996901/
- ACOG Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy
- FDA. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927-938. https://pubmed.ncbi.nlm.nih.gov/27459524/
- Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
- Fournier A, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448-454. https://pubmed.ncbi.nlm.nih.gov/18294534/
- Koonin LM, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic. MMWR Morb Mortal Wkly Rep. 2020;69(43):1595-1599. https://pubmed.ncbi.nlm.nih.gov/33573846/
- Kling JM, et al. Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents. Mayo Clin Proc. 2019;94(2):242-253. https://pubmed.ncbi.nlm.nih.gov/32852449/
- The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. https://pubmed.ncbi.nlm.nih.gov/28641885/
- Mulcahy AW, et al. Estimated savings from the Inflation Reduction Act. JAMA. 2023;329(6):502-504. https://pubmed.ncbi.nlm.nih.gov/36625825/
- Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril. 2000;73(3):516-521. https://pubmed.ncbi.nlm.nih.gov/10999749/
- Lobo RA, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial (REPLENISH). Obstet Gynecol. 2018;132(1):161-170. https://pubmed.ncbi.nlm.nih.gov/29286975/
- Friess E, et al. Progesterone-induced changes in sleep in male subjects. Am J Physiol Endocrinol Metab. 1997;272(5):E885-E891. https://pubmed.ncbi.nlm.nih.gov/11588171/